Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Amortization of Deferred Charges: 2020-2024

Historic Amortization of Deferred Charges for Kymera Therapeutics (KYMR) over the last 5 years, with Dec 2024 value amounting to -$14.0 million.

  • Kymera Therapeutics' Amortization of Deferred Charges rose 39.61% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year increase of 15.72%. This contributed to the annual value of -$14.0 million for FY2024, which is 167.41% down from last year.
  • According to the latest figures from FY2024, Kymera Therapeutics' Amortization of Deferred Charges is -$14.0 million, which was down 167.41% from -$5.2 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Amortization of Deferred Charges high stood at $5.8 million for FY2021, and its period low was -$14.0 million during FY2024.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was -$5.2 million (2023), whereas its average is -$6.1 million.
  • In the last 5 years, Kymera Therapeutics' Amortization of Deferred Charges skyrocketed by 269.64% in 2021 and then crashed by 688.19% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Amortization of Deferred Charges (Yearly) stood at $1.6 million in 2020, then soared by 269.64% to $5.8 million in 2021, then crashed by 84.69% to $889,000 in 2022, then slumped by 688.19% to -$5.2 million in 2023, then plummeted by 167.41% to -$14.0 million in 2024.